Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Segment Revenue, Operating Income and Depreciation and Amortization

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2018			2017			2016
Revenue:
Medical Device	$	60,513		$	53,983		$	53,202
In Vitro Diagnostics		20,823			19,129			18,164
Total revenue	$	81,336		$	73,112		$	71,366
Operating (loss) income:
Medical Device	$	(8,478	)	$	6,902		$	16,975
In Vitro Diagnostics		8,619			8,293			7,115
Total segment operating income		141			15,195			24,090
Corporate		(8,940	)		(8,092	)		(7,231	)
Total operating (loss) income	$	(8,799	)	$	7,103		$	16,859
Depreciation and amortization:
Medical Device	$	5,376		$	4,453		$	3,261
In Vitro Diagnostics		394			412			789
Corporate		661			690			823
Total depreciation and amortization	$	6,431		$	5,555		$	4,873

Revenue from Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

	2018			2017			2016
Medtronic		16	%		18	%		25	%
Abbott		11	%	N/A			N/A

Geographic Revenue and Long-lived Assets

Geographic revenue was as follows for the years ended September 30:

	2018			2017			2016
Domestic		79	%		77	%		79	%
Foreign		21	%		23	%		21	%

Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30:

	2018		2017
U.S.	$	26,652	$	20,949
Ireland		21,174		22,555